{"organizations": [], "uuid": "7045578a3458791cc29730bd1f35c864caf043cc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-terns-pharma-acquires-global-exclu/brief-terns-pharma-acquires-global-exclusive-rights-to-develop-and-commercialize-three-nash-assets-from-lilly-idUSASC09UUB", "country": "US", "domain_rank": 408, "title": "BRIEF-Terns Pharma Acquires Global, Exclusive Rights To Develop And Commercialize Three NASH Assets From Lilly", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.277, "site_type": "news", "published": "2018-04-04T18:10:00.000+03:00", "replies_count": 0, "uuid": "7045578a3458791cc29730bd1f35c864caf043cc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-terns-pharma-acquires-global-exclu/brief-terns-pharma-acquires-global-exclusive-rights-to-develop-and-commercialize-three-nash-assets-from-lilly-idUSASC09UUB", "ord_in_thread": 0, "title": "BRIEF-Terns Pharma Acquires Global, Exclusive Rights To Develop And Commercialize Three NASH Assets From Lilly", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "negative"}, {"name": "nash assets from lilly", "sentiment": "negative"}, {"name": "brief-terns pharma acquires global", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - Eli Lilly and Co:\n* TERNS PHARMACEUTICALS ACQUIRES GLOBAL, EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE THREE NASH ASSETS FROM LILLY\n* VALIDATED NASH TARGET * DEVELOPMENT OF CLINICAL PROGRAMS WILL FOCUS ON REGULATORY APPROVAL IN CHINA AND ADDITIONAL GLOBAL MARKETS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-04T18:10:00.000+03:00", "crawled": "2018-04-04T13:21:43.021+03:00", "highlightTitle": ""}